BioCurex Inc. filed its 10KSB on March 31, 2008 for the period ending December 31, 2007. In this report its auditor, Manning Elliot, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

BioCurex Inc. announced that the European Patent Office (EPO) has granted the Company´s patent claims for cancer diagnostic serum tests based on the RECAF marker. Approval by regulatory agencies in Europe is arguably faster and easier than by the FDA. As a result, companies may launch diagnostic tests in Europe before the USA.

BioCurex Inc. announced that it has reached an agreement in principle to amend its licensing agreement, dated April 2005, with its first Licensee as follows: The proposed amendment relieves The Licensee of future due diligence obligations to commercialize or perform further Research and Development on the RECAF technology as well as its obligation to pay the annual minimum royalty. BioCurex will continue development of a chemiluminescence based serum RECAF test in its own facilities and The Licensee may resume research and development work and commercialize products incorporating the RECAF technology as per the original agreement. In consideration for the modification, BioCurex gained a higher royalty on any RECAF products that may be sold by The Licensee. BioCurex also obtained the right to terminate the license at any time if The Licensee, following notice from BioCurex, does not agree within ninety days to new due diligence obligations for the commercialization of any products using the RECAF technology.